Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 22, Pages -Publisher
MDPI
DOI: 10.3390/ijms222212292
Keywords
ER plus breast cancer; antiestrogens; CDK4; CDK4/6 inhibitor; palbociclib; ribociclib; abemaciclib
Funding
- Public Health Service [R01-CA201092 t]
Ask authors/readers for more resources
ER+ breast cancer is the most common form, with resistance to antiestrogens leading to the development of CDK4/6 inhibitors as a successful alternative treatment option. However, resistance to these inhibitors is also common, with various mechanisms identified. Future research should focus on developing biomarkers to guide treatment strategies for resistant patients.
Estrogen receptor-positive (ER+) breast cancer is the most common form of breast cancer. Antiestrogens were the first therapy aimed at treating this subtype, but resistance to these warranted the development of a new treatment option. CDK4/6 inhibitors address this problem by halting cell cycle progression in ER+ cells, and have proven to be successful in the clinic. Unfortunately, both intrinsic and acquired resistance to CDK4/6 inhibitors are common. Numerous mechanisms of how resistance occurs have been identified to date, including the activation of prominent growth signaling pathways, the loss of tumor-suppressive genes, and noncanonical cell cycle function. Many of these have been successfully targeted and demonstrate the ability to overcome resistance to CDK4/6 inhibitors in preclinical and clinical trials. Future studies should focus on the development of biomarkers so that patients likely to be resistant to CDK4/6 inhibition can initially be given alternative methods of treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available